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Dear Editor: Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic growth factor that stimulates the proliferation and differentiation of hematopoietic cells in a bone marrow, and activates neutrophils. There are possible systemic reactions associated with G-CSF, including Sweet's syndrome, bullous pyoderma gangrenosum, leukocytoclastic vasculitis, and panniculitis 1 . Furthermore, G-CSF may induce psoriasiform dermatitis, or exacerbate pre-existing psoriasis 2 .
A 73-year-old man presented with one-month history of pruritic erythematous papules and patches on the whole body. He was diagnosed with gastric cancer and myelodysplasia 3 years ago. Cancer treatment included chemotherapy using decitabine. G-CSF therapy was initiated when the peripheral blood neutrophil level decreased below 1,000/mm 3 . After two treatments with G-CSF (1 and 3 weeks prior to presentation), the skin lesion developed. At 4 weeks after discontinuation of G-CSF, however, the lesions partially improved. And further G-CSF therapy exacerbated the lesions. The patient had no history of dermatologic diseases. The physical examination revealed erythematous variable sized scaly papules and patches on the whole body (Fig. 1A) . At the time of skin lesion onset, a blood cell count showed a white blood ). Histopathologic findings showed epidermal acanthosis, confluent parakeratosis, neutrophils in the stratum corneum (Munro's microabscess), and dilated capillaries in the dermal papillae (Fig. 1C) . Based on the clinical course, drug history, and findings of physical and histologic examination, the diagnosis of G-CSF-induced psoriasiform dermatitis was made. As no significant improvement was seen after stopping G-CSF, he was treated with 19 cycles of narrowband ultraviolet B (NBUVB) (3 times weekly), which resulted in significant improvement (Fig. 1B) . The lesions improved gradually without aggravation and side effect during NBUVB treatment. In follow-up period, he died of sepsis after ophthalmologic surgery for orbital mucormycosis. Psoriasiform dermatitis associated with G-CSF is known to be induced by increase in peripheral blood neutrophils, neutrophil activation, promotion of endothelial neutrophils adhesion, and increase in production of the neutrophil chemotactic factor interleukin-8 2, 3 . In this case, as neutrophil count increased with G-CSF therapy, the skin lesions exacerbated. When the G-CSF was stopped, the neutrophil count decreased, and the skin lesions partially improved. Rácz et al. 4 described improvements in erythema and scales in patients with imiquimod-induced psoriasiform dermatitis after NBUVB irradiation. The group with NBUVB irradiation experienced a greater decrease in epidermal neutrophil count, and angiogensis compared to that of the group without NBUVB irradiation. Ozawa et al. 5 suggested that induction of T cell apoptosis could be the major mechanism by which 312-nm UVB resolves psoriatic skin lesions. Our patient was treated with 19 cycles of NBUVB, which resulted in significant improvement. The authors think that NBUVB may show therapeutic effect by inducing T cell apoptosis and decreasing the epidermal neutrophil count and angiogenesis.
We have shown a case of G-CSF-induced psoriasiform dermatitis in a patient with myelodysplasia who had been treated with chemotherapy. Based on this case, it is important to consider G-CSF as the cause of psoriasiform dermatitis with consistent histopathologic findings in chemotherapy patients. And we report the NBUVB to be effective treatment.
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